logo
Plus   Neg
Share
Email

Rio Tinto H1 Net Profit Declines; Announces $3.5 Bln Interim Returns

Rio Tinto plc (TPPF.PK,RIO.L,RIO,RTNTF.PK) reported first-half net earnings of $4.1 billion, down 6% from prior year, due to the impairment of Oyu Tolgoi. Earnings per share in cents was 250.7 compared to 249.9. Underlying EBITDA was $10.3 billion, up 19% from prior year, excluding the $0.6 billion contribution from coking coal. The increase reflected higher iron ore prices, the company said. Basic underlying earnings per share in cents was 301.5 compared to 253.6.

First-half consolidated sales revenue was $20.7 billion, an increase of 9% from prior year, excluding the $0.8 billion contribution from the coking coal assets divested in 2018.

The company's 2019 production guidance is unchanged from its second quarter operations review.

Rio Tinto also announced returns to shareholders of $3.5 billion including interim
dividend of $2.5 billion and special dividend of $1.0 billion. The 2019 interim dividend, equivalent to 151 US cents per share, and the special dividend, equivalent to 61 US cents per share, will be paid on 19 September 2019 to shareholders on the register at the close of business on 9 August 2019.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
Follow RTT
>